Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting

100% of evaluable patients in target dose had no relapse during the four-week follow-up period
Independent objective EEG seizure analysis confirms target doseGanaxolone effective regardless of prior AED treatment and across diverse disease etiologies for RSEKOL call and live webcast on Monday, December 9th at 7:15am ETRADNOR, Pa., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (a??Marinusa?? or a??Companya??), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, announced additional data from its open-label, dose-finding Phase 2 study evaluating intravenous (IV) ganaxolone in patients with refractory status epilepticus (RSE).A  The results were presented at the American Epilepsy Society (AES) annual meeting by Eugene Ramsay, M.D., Director Emeritus, Ochsner Comprehensive Epilepsy Center in New Orleans, and investigator in the study.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »